Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02415023 | A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer | PHASE1 | COMPLETED | 34 | — | — | Nov 9, 2014 | Mar 31, 2017 | Feb 17, 2020 | 3 | China |
using RECIST v1.1 progressive disease (PD), using RECIST v 1.1
Safety and tolerance will be evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by severity in accordance with the NCI CTC AE Version 4.0.
| Arm | Type | Description |
|---|---|---|
| fruquintinib+paclitaxel | EXPERIMENTAL | fruquintinib combined with paclitaxel. Fruquintinib treatment: administration for 3 weeks followed by 1-week break, and administration every day for the first 21 days.Paclitaxel is administered once weekly in the first three weeks of each cycle. |
| Name | Type | Description |
|---|---|---|
| fruquintinib+paclitaxel | DRUG | 28-day cycle of fruquintinib qd for 3 weeks followed by 1-week break combined with paclitaxel 80 mg/m2 |
Inclusion Criteria: 1. Fully understand the study and sign the informed consent form voluntarily; 2. Patients with local advanced and/or metastatic gastric cancer confirmed by histology and/or cytology; 3. Fail in previous first-line standard chemotherapy 4. Aged 18-70years (inclusive); 5. Body wei...